Current scientific questions influencing patient management in advanced prostate cancer


Learning objective:         

After joining this meeting, participants should be able to:

  • Describe the clinical benefits of earlier treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC) and the consequences of disease progression
  • Discuss the impact of new data on treatment and management decisions for individual patients with mHSPC and nmCRPC


Scientific Committee:

  • Laura-Maria Krabbe (Germany)
  • Bertrand Tombal (Belgium)



  • Boris Hadaschik (Germany)
  • Alexandre de la Taille (France)
  • Jochen Walz (France)

More Info
1 Hours
EM-26511 - Date of preparation: June 2020